These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 27084892)
21. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes. Yamazaki H Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412 [TBL] [Abstract][Full Text] [Related]
22. Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase. Fan PW; Zhang D; Halladay JS; Driscoll JP; Khojasteh SC Drug Metab Dispos; 2016 Aug; 44(8):1253-61. PubMed ID: 27117704 [TBL] [Abstract][Full Text] [Related]
23. Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Diao X; Deng P; Xie C; Li X; Zhong D; Zhang Y; Chen X Drug Metab Dispos; 2013 Feb; 41(2):430-44. PubMed ID: 23169608 [TBL] [Abstract][Full Text] [Related]
24. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486 [TBL] [Abstract][Full Text] [Related]
25. [Research advances in non-P450-mediated drug oxidative metabolism]. Zhou L; Zhong DF; Chen XY Yao Xue Xue Bao; 2017 Jan; 52(1):8-18. PubMed ID: 29911369 [TBL] [Abstract][Full Text] [Related]
26. Recent advances: the cytochrome P450 enzymes. Slaughter RL; Edwards DJ Ann Pharmacother; 1995 Jun; 29(6):619-24. PubMed ID: 7663035 [TBL] [Abstract][Full Text] [Related]
27. Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human. Grangeon A; Gravel S; Gaudette F; Turgeon J; Michaud V J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():144-158. PubMed ID: 27978469 [TBL] [Abstract][Full Text] [Related]
28. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Karam WG; Goldstein JA; Lasker JM; Ghanayem BI Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508 [TBL] [Abstract][Full Text] [Related]
29. Drug metabolism in microorganisms. Murphy CD Biotechnol Lett; 2015 Jan; 37(1):19-28. PubMed ID: 25179825 [TBL] [Abstract][Full Text] [Related]
30. Extrahepatic metabolism of drugs in humans. Krishna DR; Klotz U Clin Pharmacokinet; 1994 Feb; 26(2):144-60. PubMed ID: 8162658 [TBL] [Abstract][Full Text] [Related]
31. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Lee IS; Kim D Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682 [TBL] [Abstract][Full Text] [Related]
32. Cytochrome P450 and the biological clock in mammals. Froy O Curr Drug Metab; 2009 Feb; 10(2):104-15. PubMed ID: 19275546 [TBL] [Abstract][Full Text] [Related]
33. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics. Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061 [TBL] [Abstract][Full Text] [Related]
34. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space. Reinen J; van Leeuwen JS; Li Y; Sun L; Grootenhuis PD; Decker CJ; Saunders J; Vermeulen NP; Commandeur JN Drug Metab Dispos; 2011 Sep; 39(9):1568-76. PubMed ID: 21673132 [TBL] [Abstract][Full Text] [Related]
35. Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance. Argikar UA; Potter PM; Hutzler JM; Marathe PH AAPS J; 2016 Nov; 18(6):1391-1405. PubMed ID: 27495117 [TBL] [Abstract][Full Text] [Related]
36. Modelling human cytochromes P450 for evaluating drug metabolism: an update. Lewis DF Drug Metabol Drug Interact; 2000; 16(4):307-24. PubMed ID: 11201309 [TBL] [Abstract][Full Text] [Related]
37. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300 [TBL] [Abstract][Full Text] [Related]
38. Medicinal chemistry of drugs with active metabolites (N-, O-, and S-desalkylation and some specific oxidative alterations). Ram N; Kalász H; Adeghate E; Darvas F; Hashemi F; Tekes K Curr Med Chem; 2012; 19(33):5683-704. PubMed ID: 22934779 [TBL] [Abstract][Full Text] [Related]
39. Microsomal cytochrome P450 as a target for drug discovery and repurposing. El-Sherbeni AA; El-Kadi AO Drug Metab Rev; 2017 Feb; 49(1):1-17. PubMed ID: 27819488 [TBL] [Abstract][Full Text] [Related]
40. Simultaneous Screening of Activities of Five Cytochrome P450 and Four Uridine 5'-Diphospho-glucuronosyltransferase Enzymes in Human Liver Microsomes Using Cocktail Incubation and Liquid Chromatography-Tandem Mass Spectrometry. Lee B; Ji HK; Lee T; Liu KH Drug Metab Dispos; 2015 Jul; 43(7):1137-46. PubMed ID: 25904760 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]